Supplemental table 1.Reasons of exclusion.

Author/registration Number / Year / Reasons of exclusion
Rojas-Rivera J et al [1]
Chen M et al [2]
NCT00302523 [3]
Liu S et al [4]
Caro J et al [5]
Sun Z et al [6]
Segarra-Medrano A et al [7]
Yuan H et al [8]
Chen W et al [9]
Sun Z et al [10]
Elena GS et al [11]
Praga M et al [12]
Ballarin J et al [13]
McCauley J et al [14]
Zhang D et al [15]
Xu J et al [16]
Xu J et al [17] / 2015
2006
2006
2015
2015
2014
2014
2013
2013
2014
2014
2007
2007
1993
2015
2010
2010 / Study protocol
Study protocol
Study protocol
The control group was treated with wilfordiimultiglycosides, instead of cyclophosphamide.
Uncontrolled study
The control group was treated with Wuzhi capsules, instead of cyclophosphamide.
Uncontrolled study
Comparing the effects between short-term and long-term treatments of tacrolimus.
Uncontrolled study
Uncontrolled study
Uncontrolled study
The control group was treated with placebo, instead of cyclophosphamide.
Uncontrolled study
Uncontrolled study
Without the report of the required data
Without the report of the required data
A duplicate report

Supplemental references

1. Rojas-Rivera J, Fernández-Juárez G, Ortiz A, et al. A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment withTAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primaryMEmbranous Nephropathy: the STARMEN study.Clin Kidney J. 2015;8:503-10.

2. Chen M, Chen J, Li X, Lu F, et al. A randomized controlled study comparing prednisone plustacrolimusversus prednisone plus cyclophosphamide in patients withmembranousnephropathyand nephrotic syndrome.J Am SocNephrol. 2006;17:802A.

3.Tacrolimustreatmentof patients with idiopathicmembranousnephropathy. clinicaltrials.gov/ct2/show/NCT00302523,2006

4. Liu S, Li X, Li H, Liang Q, et al. Comparison of tripterygium wilfordii multiglycosidesandtacrolimusin the treatment of idiopathicmembranous nephropathy: a prospective cohort study.BMC Nephrol. 2015;16:200.

5.Caro J, Gutiérrez-Solís E, Rojas-Rivera J, et al. Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus.Nephrol Dial Transplant. 2015;30:467-74.

6. Sun Z, Ren M, Wu Q, Du X. Co-administration of Wuzhi capsules andtacrolimusin patients with idiopathicmembranous nephropathy: clinical efficacy and pharmacoeconomics.IntUrolNephrol. 2014;46:1977-82.

7. Segarra-Medrano A, Jatem-Escalante E, Carnicer-Cáceres C, et al.Evolution ofantibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathicmembranous nephropathypatients treated withtacrolimus.Nefrologia. 2014;34:491-7.

8. Yuan H, Liu N, Sun GD, Jia Y, Luo P, Miao LN. Effectof prolongedtacrolimustreatmentin idiopathicmembranousnephropathywithnephrotic syndrome.Pharmacology. 2013;91:259-66.

9. Chen W, Liu Q, Liao Y, et al. Outcomes oftacrolimustherapy in adults with refractorymembranousnephrotic syndrome: a prospective, multicenter clinical trial. Am J Med Sci. 2013;345:81-7.

10.SunZ,RenM,WuQ,DuX.Co-administration of wuzhi capsules and tacrolimus in patients with idiopathic membranous nephropathy: clinical efficacy and pharmacoeconomics. Int Urol Nephrol.2014;46:1977-82.

11. ElenaGS,JaraEP,EnriqueRJ,ManuelP.Predictors of response and relapse in patients with primary membranous nephropathy trated with tacrolimus. Nephrol Dial Transplant.2014;29 (Suppl 3): iii190.

12.Praga M, Barrio V, Juárez GF, et al. Tacrolimusmonotherapy inmembranous nephropathy: a randomized controlled trial.Kidney Int. 2007;71:924-30.

13. Ballarin J,Poveda R,Ara J,et al. Treatment ofidiopathic membranous nephropathywith the combination of steroids,tacrolimusand mycophenolate mofetil: results of a pilot study. Nephrol Dial Transplant.2007;22:3196-201.

14. McCauley J,Shapiro R,Ellis D,et al. Pilot trial of FK 506 in the management of steroid-resistantnephrotic syndrome. Nephrol Dial Transplant.1993;8:1286-90.

15.Zhang D, Zheng H, Shang LI. Long-term efficacy and safety study of tacrolimus combined with corticosteroids in the treatment of idiopathic membranous nephropathy. Hong Kong Journal of Nephrology.2015;17(Suppl1): S65.

16. XuJ,ZhangW,XuY,ChenN.A double-blinded prospective randomised study on the efficacy of corticosteroid plus cyclophosphamide or FK506 in idiopathic membranous nephropathy patients with nephrotic syndrome. NDT Plus.2010;3(Suppl 3): iii431.

17.XuJ,ZhangW,XuY,ChenN.A double-blinded prospective randomised study on the efficacy of corticosteroid plus cyclophosphamide or FK506 in idiopathic membranous nephropathy patients with nephrotic syndrome.Nephrology.2010; 15(Suppl 3):43.